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Summary Background: Endothelin-1 (ET-1) has been implicated in the pathogenesis
of asthma and chronic obstructive pulmonary disease (COPD). The ET-1 levels are
elevated during exacerbations of asthma and COPD in bronchoalveolar lavage, serum,
and sputum and fails with treatment of the exacerbations. Hypoxemia stimulates ET-1
secretion. Objective: The aim of this study was to examine the serum ET-1 levels in
stable asthmatic and COPD patients. Materials and methods: We examined 48 COPD and
26 asthmatic patients and 34 normal subjects. We collected arterial samples to measure
baseline ET-1 levels in all patients and in the control group, during the day. All the
patients underwent formal polysomnography (EEG, ECG, airflow, respiratory muscle
movement, oximeter) to detect the presence of nocturnal, nonapneic, and oxyhemoglo-
bin desaturation. Twelve of the COPD patients and six of the asthmatic patients were
disqualified because of inadequate sleep or sleep apnea syndrome. Nineteen of the COPD
patients desaturated below a baseline sleep saturation of 90% for 5min or more, reaching
a nadir saturation of at least 85%. We collected arterial samples to measure ET-1 levels,
5min after the first period of desaturation in each of the 19 desaturators COPD patients.
None of the 20 asthmatic patients exhibited oxyhemoglobin desaturation during sleep.
Results: Baseline arterial ET-1 levels during the day were significantly higher in
‘‘desaturators’’ COPD patients (2.0870.28pg/ml) compared to ‘‘non-desaturators’’
COPD patients (1.3870.16pg/ml) (Po0:001) and to asthmatics (0.7270.85pg/ml)
(Po0:001). ET-1 levels in normal subjects were 1.22170.02pg/ml. In ‘‘desaturators’’
COPD patients ET-1 levels during the night, 5min after the first oxyhemoglobin
desaturation, were significantly higher (4.2871.10pg/ml) compared to those during the
day (2.0870.28pg/ml) (Po0:001). A significant negative correlation was observed
between ET-1 levels and degree of desaturation during the day (P ¼ 0:005; r ¼ 0:632)
and during the night (Po0:001; r ¼ 0:930) in ‘‘desaturators’’ COPD patients. Conclusion:
According to our results: (1) ET-1 levels were significantly higher in ‘‘desaturators’’ COPD
patients than in ‘‘non-desaturators’’ COPD and in asthmatics; (2) ET-1 levels were
significantly higher during the night than during the day in ‘‘desaturators’’ COPD patients;
(3) the degree of desaturation correlated negatively with the ET-1 levels in
‘‘desaturators’’ COPD patients, both during daytime and nighttime. These findings are
consistent with the hypothesis that ET-1 is implicated in the pathophysiology of asthma
and COPD, especially if nocturnal, nonapneic, oxyhemoglobin desaturation exists.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
The endothelins are peptides of 21 amino acids that
are produced in a wide variety of cells. Endothelin-
1 (ET-1) is produced in endothelial cells, in vascular
smooth-muscle cells and in other cells of the
bronchial epithelium.1 Bronchial epithelial cells of
asthmatic patients show increased expression of
ET-1.2 ET-1 is raised in the airways of asthmatic
subjects and has been shown to stimulate mucus
secretion, airway edema, smooth-muscle mitogen-
esis and bronchial hyper-responsiveness.3 ET-1
produces prolonged and potent contraction of
animal and human airways in vitro4 and in animal
studies in vivo by aerosol administration.5 It is
also thought to have proinflammatory effect in
the airways, being both a chemoattractant and
upregulator of other inflammatory mediators
such as interleukins IL-6 and IL-8.6,7 Plasma and
bronchoalveolar lavage levels of ET-1 have been
reported to be elevated in acute exacerbation
of asthma falling with treatment of the exacerba-
tion and to correlate with clinical severity of
asthma.8,9
ET-1 is elevated by hypoxia, which may act both
to increase ET-1 expression by increasing the
binding of transcription factors such as AP-1 to
the ET-1 gene and by increasing the activity of
endothelin-converting enzymes.10–12 ET-1 is be-
lieved to be one of the factors mediating pulmon-
ary hypertension, at altitude and with congestive
heart failure, for example and it has been
implicated in cor pulmonale.13 Hyperoxia also
increases ET-1 levels and the action is believed to
be mediated by the formation of reactive oxygen
species.13 Intermittent hypoxia has been shown to
produce the same effects as chronic hypoxia and at
times even more rapidly.14 It may be that repetitive
episodes of hypoxia and normoxia cause oxygen
radical formation similar to ischemia followed by
reperfusion.14 If this is true, it is possible that
adverse effects depend on the clustering of
hypoxic/normoxic episodes and not just the dura-
tion of hypoxia.12,14
Nonapneic, oxyhemoglobin desaturation asso-
ciated with sleep has been described in patients
with chronic obstructive pulmonary disease
(COPD),15–18 cystic fibrosis,19,20 interstitial lung
disease21,22 and neuromuscular or skeletal diseases
affecting the thorax.23,24 These often profound,
decreases in oxyhemoglobin saturation (SatO2) may
be accompanied by marked elevation of pulmonary
arterial pressure.25–27 Repetitive, transient epi-
sodes of nocturnal hypoxemia have been proposed
as one mechanism by which chronic pulmonary
hypertension can develop in patients with ad-
vanced lung disease.28,29
The aim of this study was to examine the ET-1
serum levels in stable asthmatic and COPD pa-
tients, with and without nocturnal, nonapneic,
oxyhemoglobin desaturation. According to our
knowledge this is the first study, which examines
the day, and night variability of hemoglobin
saturation (SatO2) in correlation with ET-1
serum levels in asthmatic and COPD patients in
remission.
Materials and methods
We examined 48 COPD and 26 asthmatic patients
who met the requirements and agreed to partici-
pate, in this study. We also examined 34 normal
controls. The study was approved from the Patras
University Hospital Ethics committee and written
informed consent was obtained from each patient.
Twelve of COPD and six of asthmatics patients were
disqualified because of inadequate sleep or sleep
apnea syndrome.
The inclusion criteria for the COPD patients were
a clinical diagnosis of COPD according to American
Thoracic Society recommendations and a spirome-
try consistent with moderate COPD (stage IIa)
(50%o forced expiratory volumeFFEV1o80%
of predicted, FEV1/forced vital capacityF
FVCo0.70).30 Forced spirometry was performed
before the day of nocturnal polysomnography.
Three average daytime resting PaO2 were up to
60mmHg with samples spread over 3–6 months
preceding polysomnography. Daytime PaO2 values
were taken as the average of three blood gas levels
drawn with the patient seated. All patients were
estimated to be clinically stable at the time of the
study. All the asthmatics were outpatients and had
moderate asthma in remission (50%oFEV1o80%).31
They underwent skin-prick testing and measure-
ment of their bronchial reactivity by a modification
of the method of Chai et al.32 For this visit patients
with asthma were asked to withhold short-acting
b2-agonist therapy and inhaled corticosteroids for a
minimum of 6 h.
None of the patients was receiving systematic
corticosteroids. The atopic status was determined
using the following common aeroallergens: mixed
grass, pollens, dermatophagoids, pterenyssinus,
mixed leathers, cat fur and dog hair. The asth-
matics were all atopic with wheal reaction of 2mm
diameter or greater, in response to one or more of
the above aeroallergens in the presence of negative
saline and positive histamine controls.
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Their mean PC20 methylcholine was 0.56þ
0.27mg/ml. Five of the COPD patients were atopic
to one or more aeroallergens.
All the patients underwent standard full-night
polysomnography performed in a quite, partially
soundproof room, with stable humidity and tem-
perature. Each subject slept at least one night in
our laboratory. Electroencephalographic (C3A2 and
C4A1) bitemporal electrooculographic, submental
electromyographic leads were placed appropri-
ately. Nasal and oral airflow were detected by a
thermistor analyzer attached to a loose-fitting
facemask. Thoracic and abdominal pneumobelts
connected to pressure transducers detected
changes in chest and abdominal wall circumfer-
ence. Oxygen saturation (SaO2) was continuously
monitored by an oximeter. All parameters were
recorded simultaneously on polygraphic records
(Somnostar-a. Series Sensor Medics Company).
Sleep stages were scored by a trained physician
according to standard criteria.33
Nocturnal desaturation was defined as a baseline
awake saturationX90% with a fall below this value
for a period of 5min or more. During the period of
desaturation, the nadir value had to reach 85% or
lower, but was not required to remain below 85%
for at least 5min. These periods usually coincided
with but were not limited to REM sleep. Not all
patients exhibited oxyhemoglobin desaturation
during sleep.
We collected arterial samples from the 19
‘‘desaturators’’ COPD patients, 5min after the first
desaturation, from the radial artery through a
Becton–Dickinson catheter (arterial canulla with
Flow Switch 20 G/10 45mm, Ohmeda Swindon,
UK) to measure ET-1 levels. Only one sample per
‘‘desaturator’’ patient was collected during the
polysomnography. None of the asthmatic patients
exhibited desaturation. The observer also collected
arterial samples in the morning before the study to
measure baseline ET-1 levels in both groups.
Arterial blood for measuring ET-1 levels was
collected in chilled vacutainers containing diso-
dium dihydrogen ethylenediamine tetra-acetate
dihydrate, and then centrifuged at 3000 g for
20min, to obtain plasma. The plasma was aliquoted
and frozen at 801C until analysis. Arterial ET-1
levels were measured by radioimmunoassay. The
samples were extracted using 18 cartridges (Sep-
Pak, Waters, Missisanga, Ont., Canada) activated
by methanol. Samples and standards (synthetic ET-
1; Peptide Institute, Osaka, Japan) were reconsti-
tuted in assay buffer and incubated with rabbit
andiendothelin-1 antiserum (Peninsula Labora-
tories, Belmont, CA, USA) at 41C for 24 h. This
was followed by the addition of I-125-labeled ET-1
(Amersham International, Amersham, UK) and a
second 24 h incubation. Bound and free radio-
activity was separated by the second antibody
method and the gamma emission from the pre-
cipitate of antibody ET-1 complexes was counted
using a gamma counter. The intra- and inter-assay
coefficients of variation were 10% and 13%,
respectively. Data following normal distribution
have been presented as meanþ standard deviation
(SD). When the distribution was not normal, median
range has been used. We used Kruskal–Wallis test
for differences between unrelated groups more
than two. For differences between two related
groups Wilcoxon sign ranks test has been used. For
differences between two unrelated groups Mann–
Whitney test has been used. One way ANOVA was
used for differences in age. A P value of less
than 0.05 two tailed was considered statistically
significant.
Results
Asthmatic patients were statistically significant
younger than the ‘‘non-desaturators’’ and ‘‘desa-
turators’’ COPD patients (Po0:001) (Table 1).
There was no statistically significant difference
among blood hemoglobin (mg/ml), total sleeptime
(min), REM sleep (min) and NREM sleep (min) in all
three groups of patients (Table 1).
The FEV1 (in 1 s)/FVC ratio of our asthmatic
patients in remission, was statistically significantly
higher than that of our ‘‘non-desaturators’’
(P ¼ 0:02) and of our ‘‘desaturators’’ COPD patients
(Po0:001) (Table 1, Fig. 1). The FEV1/FVC ratio
between ‘‘desaturators’’ and ‘‘non-desaturators’’
COPD patients was not statistically significant
(P ¼ 0:09) (Table 1). ‘‘Desaturators’’ had signifi-
cantly lower FEV1 and FVC, but the overlap
between groups was sufficient to make these
parameters alone of little help in separating
individual ‘‘desaturator’’.
The daytime SatO2 level of our asthmatics was
statistically significantly higher than that of our
‘‘non-desaturators’’ (Po0:001) and of our ‘‘desa-
turators’’ COPD patients (P ¼ 0:005) (Fig. 2). No
statistically significant difference was observed in
the daytime SatO2 level between ‘‘non-desatura-
tors’’ and ‘‘desaturators’’ COPD patients (P ¼ 0:8)
(Table 1). The daytime baseline ET-1 levels in
asthmatic patients were statistically significantly
lower than those observed in ‘‘non-desaturators’’
COPD patients (Po0:004) and in ‘‘desaturators’’
COPD patients (P ¼ 0:01). The daytime ET-1
levels in asthmatic, ‘‘non-desaturators’’ and
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‘‘desaturators’’ COPD patients and in normal con-
trols are presented in Fig. 3. The daytime baseline
ET-1 levels in ‘‘desaturators’’ COPD patients was
statistically significantly higher than that of ‘‘non-
desaturators’’ COPD patients (P ¼ 0:005). The
‘‘desaturators’’ COPD patients had statistically
significant higher levels of ET-1 during the
night than during the day (Po0:001) (Fig. 4;
Table 2).
In ‘‘desaturators’’ COPD patients existed a
relationship between ET-1 blood levels and SatO2.
ET-1 levels were negatively statistically signifi-
cantly correlated with nadir values of oxyhe-
moglobin desaturation during sleep (Po0:001;
r ¼ 0:939) (Fig. 5) and during daytime (P ¼
0:005; r ¼ 0:632) (Fig. 6). No statistically signifi-
cant correlation between ET-1 blood levels and
SaO2 was observed in the other groups.
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Figure 1 FEV1/FVC ratio in asthmatic and COPD ‘‘non-
desaturators’’ and ‘‘desaturators’’ patients.
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Figure 3 ET-1 in asthmatic and COPD ‘‘non-desatura-
tors’’ and ‘‘desaturators’’ patients and normal controls
during daytime.
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Figure 2 SatO2 in asthmatic and COPD ‘‘non-desatura-
tors’’ and ‘‘desaturators’’ patients during daytime.
Table 1 Age, blood hemoglobin, sleep stages, arterial gases and spirometric values in asthmatic and COPD ‘‘non-
desaturators’’ and ‘‘desaturators’’ patients (mean7SD).
Asthmatic patients COPD non-desaturators
patients
COPD desaturators
patients
Age (years) 55.70712.80 60.2974.80 63.0073.16
Blood hemoglobin (mg/ml) 14.3071.10 15.1371.00 15.0670.98
Total sleep time (min) 317.30771.96 299.22744.10 294.19757.94
REM sleep (min) 49.62714.22 38.62713.94 44.79714.68
NREM sleep (min) 282.37736.18 260.67734.08 250.56748.08
SatO2 (%) 95.1673.18 93.5471.07 91.6071.08
PaO2 (mmHg) 87.0875.49 73.9975.28 68.0574.70
PaCO2 (mmHg) 36.8076.50 41.4172.98 42.3872.98
FEV1 (l) 1.4270.14 1.3370.29 1.0670.11
FVC (l) 2.1271.00 3.2870.43 2.9070.47
FEV1/FVC 67.95712.85 41.0579.08 37.0475.25
N 20 17 19
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Discussion
In this study, we examined ET-1 plasma levels both
in asthmatics and in COPD patients in remission, in
relation with nocturnal, nonapneic, oxyhemoglobin
desaturation.
The main site of ET-1 production is considered to
be the bronchial epithelium and the endothelium
(ETB-2) of pulmonary arteries.2,34 ET-1 is a member
of a family of 21-amino-acid peptides.10,11,14 It is
formed by a gene located on chromosome 6 whose
activation leads to the formation of a 208-amino-
acid prepo-endothelin peptide which is cleaved by
the enzyme furin convertase to a 38-amino-acid
endothelin peptide (big endothelin) and subse-
quently mainly by endothelin-converting enzyme
to the 21-amino-acid form that circulates in the
plasma.10,11,14 ET-1 binds to two different kinds of
receptors, ETA and ETB. ETA is found on smooth-
muscle cells and mediates vasoconstriction via an
increase in intracellular calcium.10,11,14 ETB recep-
tors are found both in the ETB-2 and in smooth
muscle (ETB-1).10,11,14 ETB-1 receptors produce
relaxation and ETB-2 constriction.10,11,14
Hypoxia is an important stimulus for ET-1
production10–12 and it has been implicated in the
pathogenesis of pulmonary hypertension and cor
pulmonale.35 ET-1 is elevated in primary and
secondary pulmonary hypertension10,14,36 and in a
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Table 2 ET-1 levels in asthmatic and COPD ‘‘non-
desaturators’’ and ‘‘desaturators’’ patients during
daytime.
Asthmatic
patients
COPD non-
desaturators
patients
COPD
desaturators
patients
1 1.817 1.30 1.80
2 3.640 1.20 2.40
3 0.200 1.20 2.10
4 1.234 1.50 2.20
5 0.484 1.50 2.50
6 0.210 1.50 1.80
7 0.320 1.80 1.80
8 0.320 1.40 2.10
9 0.316 1.50 1.90
10 0.420 1.40 1.90
11 0.646 1.40 1.90
12 0.205 1.50 1.80
13 0.083 1.30 2.10
14 1.607 1.30 2.60
15 0.024 1.20 2.30
16 0.368 1.20 2.20
17 0.192 1.30 2.00
18 0.474 1.90
19 0.836 1.80
20 1.011
ET-1 (pg/ml)
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Figure 5 Correlation of SatO2 and ET-1 levels in
‘‘desaturators’’ COPD patients during sleep (Po0:001;
r ¼ 0:939).
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Figure 4 ET-1 in ‘‘desaturators’’ COPD patients during
daytime and during sleep.
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Figure 6 Correlation of SatO2 and ET-1 levels in
‘‘desaturators’’ COPD patients during daytime
(P ¼ 0:005; r ¼ 0:632).
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number of diseases including some cases of
systemic hypertension (particularly among Afro-
Americans), renal ischemia and congestive heart
failure.14 Also, ET-1 is a mitogen and a leucocyte
attractant and promotes the formation of several
growth factors like vascular endothelial growth
factor.14
In our asthmatic patients, nocturnal oxyhemo-
globin desaturation, and elevated ET-1 plasma
levels during the night were not observed. Sleep
apnea or oxyhemoglobin desaturation are not more
frequent in asthmatics than in healthy subjects.37
In accordance with this finding, all our asthmatic
patients did not exhibit sleep apnea or oxyhemo-
globin desaturation It seems that asthmatics in
remission are not prone to exhibit oxyhemoglobin
desaturation during sleep and ET-1 production as a
consequence of this mechanism.
In our COPD patients, nocturnal oxyhemoglobin
desaturation and elevated ET-1 plasma levels
during sleep were observed in 19 subjects. Sleep-
related hypoventilation, airway obstruction, hyper-
inflation, respiratory muscle dysfunction, blunted
ventilatory responses to hypercapnia and/or
hypoxia, ventilation–perfusion mismatching and
medications can all contribute to this sleep oxygen
desaturation in COPD patients, observed also
in previous studies.38–40 In agreement with previous
studies, our ‘‘non-desaturators’’ COPD patients
had lower levels of ET-1 than the ‘‘desaturators’’
when awake.41,42 Our patients had chronic and
severe hypoxia and elevated ET-1 levels. Chronic
and severe hypoxemia may be associated with
the increase in the plasma ET-1 levels in COPD
patients via an increase in local production and
an increment in the systemic concentration.
43 Also, the clustering of hypoxic/normoxic
episodes during sleep, and not just the duration
of hypoxemia, may be associated with the
increase in the plasma ET-1 levels in COPD
patients.12,14
According to our study, ET-1 levels were signifi-
cantly higher in ‘‘desaturators’’ COPD patients than
in ‘‘non-desaturators’’ COPD patients and in asth-
matic patients during the daytime. The degree of
oxyhemoglobin desaturation correlated negatively
with the ET-1 levels in ‘‘desaturators’’ COPD
patients both during daytime and sleep. Our
findings are consistent with the hypothesis that
ET-1 plays an important role in the pathophysiolo-
gical manifestations of bronchial asthma and COPD.
‘‘Desaturators’’ COPD patients might be in higher
risk to develop cardiovascular complications than
‘‘non-desaturators’’ COPD patients because of the
nonapneic, oxyhemoglobin desaturation associated
with sleep.
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